Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | BRD4 | O60885 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13628941 | 1.00 | MAPT (0.60) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL3737334 | 1.00 | MAPT (0.60) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL11345591 | 0.94 | MAPT (0.53) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL11568552 | 0.86 | NPC1 (0.66) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL12264384 | 0.86 | SMN1; SMN2 (0.62) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL2547131 | 0.86 | SMN1; SMN2 (0.62) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL20291763 | 0.85 | MAPT (0.58) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL18548859 | 0.85 | MAPT (0.58) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL15164801 | 0.85 | MAPT (0.58) | MAPTRAB9ANPC1SMN1; SMN2KMT2A | |
| SCHEMBL10862595 | 0.83 | MAPT (0.58) | MAPTRAB9ANPC1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7826982-B2 | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-11-02 | — | — | US | disclosed |
| US-7826982-B2 | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-11-02 | — | — | US | disclosed |
| US-7826982-B2 | Method of identifying inhibitors using a 3-D structure of RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-11-02 | — | — | US | disclosed |
| US-7612080-B2 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612080-B2 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-11-03 | — | — | US | disclosed |
| US-7517890-B2 | GTPase inhibitors and methods of use | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517890-B2 | GTPase inhibitors and methods of use | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-04-14 | — | — | US | disclosed |
| US-7517890-B2 | GTPase inhibitors and methods of use | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2009-04-14 | — | — | US | disclosed |
| EP-1920048-A2 | GTPASE INHIBITORS AND METHODS OF USE AND CRYSTAL STRUCTURE OF RAC-1 GTPASE | Children's Hospital Medical Center (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1814553-A2 | GTPASE INHIBITORS AND USE THEREOF FOR CONTROLLING PLATELET HYPERACTIVITY | Children's Hospital Medical Center (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20070155766-A1 | GTPase inhibitors and methods of use and crystal structure of RAC-1 GTPase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| US-20070155766-A1 | GTPase inhibitors and methods of use and crystal structure of RAC-1 GTPase | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-07-05 | — | — | US | disclosed |
| WO-2007016539-A2 | GTPASE INHIBITORS AND METHODS OF USE AND CRYSTAL STRUCTURE OF RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016539-A2 | GTPASE INHIBITORS AND METHODS OF USE AND CRYSTAL STRUCTURE OF RAC-1 GTPASE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1691812-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060135542-A1 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-06-22 | — | — | US | disclosed |
| WO-2006055833-A2 | GTPASE INHIBITORS AND USE THEREOF FOR CONTROLLING PLATELET HYPERACTIVITY | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2006-05-26 | — | — | WO | disclosed |
| US-20060004032-A1 | GTPase inhibitors and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-01-05 | — | — | US | disclosed |
| WO-2005051392-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2005051392-A1 | GTPASE INHIBITORS AND METHODS OF USE | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135542-A1 | GTPase inhibitors and use thereof for controlling platelet hyperactivity | ARHGDIB, ARHGEF2, RAC1 | MAPT 3929/4885RAB9A 101/4885NPC1 4294/4885 |
| US-20060004032-A1 | GTPase inhibitors and methods of use | RAC1, RAC2, ARHGDIB | MAPT 2697/4885RAB9A 79/4885NPC1 4018/4885 |
| US-20070155766-A1 | GTPase inhibitors and methods of use and crystal structure of RAC-1 GTPase | RAC1, RAC2, RAC3 | MAPT 2389/4885RAB9A 74/4885NPC1 3641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.